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Abstract
Purpose We performed a detailed analysis of sensory function in patients with chronic post-surgical neuropathic pain (NP) 
after breast cancer treatments by quantitative sensory testing (QST) with DFNS (German Research Network on Neuropathic 
Pain) protocol and bed side examination (BE). The nature of sensory changes in peripheral NP may reflect distinct patho-
physiological backgrounds that can guide the treatment choices. NP with sensory gain (i.e., hyperesthesia, hyperalgesia, 
allodynia) has been shown to respond to  Na+-channel blockers (e.g., oxcarbazepine).
Methods 104 patients with at least “probable” NP in the surgical area were included. All patients had been treated for breast 
cancer 4–9 years ago and the handling of the intercostobrachial nerve (ICBN) was verified by the surgeon. QST was con-
ducted at the site of NP in the surgical or nearby area and the corresponding contralateral area. BE covered the upper body 
and sensory abnormalities were marked on body maps and digitalized for area calculation. The outcomes of BE and QST 
were compared to assess the value of QST in the sensory examination of this patient group.
Results Loss of function in both small and large fibers was a prominent feature in QST in the area of post-surgical NP. QST 
profiles did not differ between spared and resected ICBN. In BE, hypoesthesia on multiple modalities was highly prevalent. 
The presence of sensory gain in BE was associated with more intense pain.
Conclusions Extensive sensory loss is characteristic for chronic post-surgical NP several years after treatment for breast 
cancer. These patients are unlikely to respond to  Na+-channel blockers.
Keywords Post-surgical pain · Neuropathic pain · Quantitative sensory testing · Sensory mapping
Introduction
Chronic post-surgical neuropathic pain (NP, ICD 11 codes 
MG30.51 Chronic neuropathic pain after peripheral nerve 
injury and MG30.11 Chronic post cancer treatment pain) 
is common after breast cancer surgery with an estimated 
prevalence of 14–31% [1, 2]. This condition may persist 
for years [3, 4]. Surgical trauma to the intercostobrachial 
nerve (ICBN) is postulated as a major cause of both sensory 
impairment and NP [5, 6] although injuries to other nerves 
(e.g., intercostal nerves) may also contribute to post-surgical 
NP [7].
The features of sensory dysfunctions in peripheral NP 
may reflect distinct pathophysiological backgrounds with 
different responses to medical treatments [8–11]. Clinical 
bedside examination (BE) of sensory function is the essen-
tial first step of demonstrating “the presence of a lesion or 
disease of the somatosensory system” in the diagnostic 
workup of NP [12]. Quantitative sensory testing (QST) 
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allows for more detailed and quantified assessment of sen-
sory function. Recent studies on standardized QST protocol 
developed by the DFNS (German Research Network on Neu-
ropathic Pain) have provided new data of sensory profiles 
across NP etiologies [13, 14].
After breast cancer surgery, sensory loss in QST is a 
prominent finding, although some patients present with 
sensory gain [15–17]. However, QST studies in this patient 
group are scarce, especially with long follow-up after sur-
gery. Previous studies using DFNS QST for post-surgical NP 
in general have included both surgical and traumatic etiolo-
gies [18–20] or have had a small cohort [21]. Patients with 
orthognathic surgery showed postoperative sensory loss, but 
recovered well in three month follow-up [21]. To the best 
of our knowledge, no studies using the DFNS QST protocol 
have been conducted in the breast cancer surgery patient 
group before.
Our study had two aims. Firstly, we wanted to perform 
a detailed sensory characterization of patients with chronic 
post-surgical NP several years after treatments. We assessed 
QST by the DFNS protocol and performed sensory mapping 
by detailed BE. Secondly, we wanted to assess what added 
value QST might offer to the clinical BE in this patient 
group. For this, we compared the outcomes of QST and 
BE. With these measures, we aimed to improve understand-




All patients were recruited from a previous cohort of 1000 
women operated for breast cancer at the Helsinki University 
Hospital during 2006–2010 [22]. 402 of them participated 
in a new study (project acronym NeuroPain) on post-surgi-
cal NP during 2014–2016. Patients with a surgeon-verified 
ICBN resection and patients who had reported post-surgical 
pain in the annual follow-up questionnaires were invited. 
Patients under 75 years were included.
We graded the diagnosis of NP according to the revised 
diagnostic criteria of NP [23]. For the current study, we 
included patients who reached the diagnostic level of “prob-
able” NP, i.e., patients who had relevant pain history in the 
neuroanatomically plausible area and at least one abnormal 
clinical sensory finding at the site of pain in BE [4, 23]. 
We excluded patients with breast reconstruction, bilateral 
surgery, bilateral pain, or other reason that may affect sen-
sory function (e.g., previous varicella zoster eruption), and 
psychiatric/cognitive reasons.
The research-visit included a structured neurological 
examination with pain assessments and BE for sensory 
function of the upper body. The examining neurologist (HH) 
was blinded to the ICBN resection status. Patients gave self-
reports of their current medication. The eligible patients 
were invited for the QST. Two DFNS-certified nurses per-
formed QST. The study was registered in the ClinicalTrials.
gov (NCT02487524).
Cancer treatments
The data of cancer treatments were available from the pre-
vious study [22]. The surgical procedure was either mas-
tectomy or breast conserving resection (BCR) accompanied 
with either sentinel lymph node biopsy (SLNB) or axillary 
lymph node dissection (ALND). The operating surgeon 
registered the ICBN handling on a 4-point categorical 
scale (spared, partially or totally resected, not visualized). 
The oncological treatments were administered according 
to national treatment protocols. Chemotherapy regimen 
consisted of a combination of docetaxel and CEF (cyclo-
phosphamide, ebirubicine, and 5-fluorouracil). Endocrine 
therapy consisted of tamoxifen (premenopausal women) or 
aromatase inhibitor (postmenopausal women).
Pain assessments
We use the term “surgical area” for the operated breast and 
the area that is neuroanatomically plausible for the ICBN 
lesion (lateral breast, upper chest wall, axilla, medial upper 
arm) [24].
For self-reported pain we used Brief Pain Inventory (BPI) 
[25] to rate the worst pain past week in the surgical area with 
Numerical Rating Scale, NRS 0–10, and marked the pain 
localization on a body map. For evoked pain at BE, we asked 
patients to rate their pain by NRS 0–10 and the examiner 
marked the pain site on a body map.
Quantitative sensory testing
QST was performed by using the DFNS protocol and the 
equipment approved by DFNS [26]. Two nurses were trained 
in a DFNS-certified laboratory (September 2015, Neuro-
physiology, University Medicine Mannheim, Heidelberg 
University, Mannheim, Germany). QST was conducted at 
the most representative site of NP (i.e., the site with most 
intensive pain accompanied with sensory findings) within 
the surgical area and the corresponding area at the unaf-
fected side.
The QST data for each individual patient were compared 
with the reference values from the DFNS normative data for 
the anatomically closest area of the thoracic wall [27]. The 
reference values are matched for age and sex. In addition, 
we used the unaffected contralateral area as reference when 
evaluating QST abnormality.
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The DFNS QST studies the function of Aβ-, Aδ- and 
C-fibers with the following 13 tests: cold and warm detection 
thresholds (CDT and WDT), thermal sensory limen (TSL, 
ability to detect thermal changes), paradoxical heat sensa-
tions (PHS, reports of heat when the temperature is cooling), 
cold and heat pain thresholds (CPT and HPT), mechanical 
detection threshold (MDT), mechanical pain threshold and 
sensitivity (MPT and MPS), wind-up ratio (WUR, pain after 
repetitive pinprick stimulation), dynamical mechanical allo-
dynia (DMA), pressure pain threshold (PPT), and vibration 
detection threshold (VDT).
VDT was performed on the clavicle for both the surgical 
and the corresponding unaffected side. All other tests were 
performed on the most representative area of NP and the 
respective contralateral area. Thermal tests were performed 
with Medoc TSA 2001-II (Ramat Yishai, Israel).
We tested the equivalence of QST and BE outcomes by 
comparing abnormal QST findings with sensory signs at 
BE. The QST finding was considered abnormal if the dif-
ference to the unaffected side exceeded 95% CI of the side-
to-side difference in the normative data [27]. The outcomes 
were regarded equal for the following outcome pairs (BE/
QST): sensory loss/abnormal loss of function; sensory gain/
abnormal gain of function; no sensory abnormalities/normal 
function.
Based on the DFNS QST, according to the recently pub-
lished algorithm [13, 14], the patients were categorized to 
four different sensory phenotypes, which have been demon-
strated to relate to experimentally induced models of neu-
ropathy [28].
Bedside examination
BE covered the upper body. The following five modalities 
were tested: light touch (cotton tuft), dynamic allodynia 
(painter’s brush), static allodynia (compressing by finger), 
pinprick (wooden cocktail stick), cold and warm sensation 
(metal roller). The following sensory abnormalities were 
assessed for each modality: hypoesthesia (decreased sen-
sitivity), hyperesthesia (increased sensitivity), dysesthesia 
(unpleasant sensation), hyperalgesia (pain evoked by pin-
prick), and allodynia (pain elicited by a non-painful stimu-
lus). The unaffected side and the surrounding upper body 
areas, were used as reference. The examining researcher 
marked the areas and types of sensory abnormalities on a 
body map for each patient.
For data digitalization, we assessed sensory loss and sen-
sory gain separately. In the digitalized images, we defined 
the area of sensory loss as that consisting of hypoesthesia 
in any of the tested sensory modalities. Likewise, the area 
of sensory gain was defined as consisting of hyperesthesia, 
hyperalgesia, dysesthesia, and allodynia in any of the sen-
sory modalities. For area calculation, we used digitalized 
body maps. We overlapped these areas for illustration and 
scaled to the size of 9.0 × 15.0 cm. We report the areas of 
sensory abnormalities in arbitrary units (1 arbitrary unit cor-
responds to 1  cm2). We used Incscape 0.92 for area calcula-
tion and image creation.
Statistical analyses
The values of 11 QST items (excluding PHS and DMA) 
were z-transformed by using the mean and standard devia-
tion of the normative data. Z-score of zero represents the 
mean of the normative data. Z-scores above zero indicate 
gain of function and z-scores below zero indicate loss of 
function. Z-scores outside 95% CI of the normative data 
were considered abnormal.
PHS is shown as the number of occurrence (0–3) and 
DMA is shown as log NRS (0–100). For group comparisons, 
we used Student t-test (two groups) and ANOVA (more than 
two groups) for normally distributed continuous variables. 
For non-normally distributed continuous variables we used 
Mann–Whitney U test (two groups) and Kruskall Wallis test 
(more than two groups). We used χ2 test for categorical vari-
ables. Correlations were assessed with Spearman’s rho  (rS). 
Linear regression analysis was used to investigate the asso-
ciation of the area of sensory loss and pain intensity. Logistic 
regression analysis was used for the association between the 
presence of sensory gain and pain intensity. p values < 0.05 
were considered statistically significant.
Results
Patient description
Figure 1 illustrates the patient flow. Of the 402 women oper-
ated for breast cancer and studied in the NeuroPain project, 
233 patients had pain in the surgical area with associating 
clinical sensory signs, i.e., probable NP. 110/233 (47%) were 
excluded and 19/104 (18%) refused QST. Reconstruction 
was the most common reason for exclusion. 104 patients 
were examined for the current study.
Since many patients had multiple painful sites within 
the surgical area, the most representative area of NP was 
selected for QST. QST was performed on the breast for 
43/104 (41%) and on the ICBN area for 61/104 (59%).
Patient characteristics and treatment-related factors are 
summarized in Table 1. 22/104 (21%) patients reported at 
least moderate (NRS 4–10) pain in the surgical area. At 
clinical examination, 79/101 (78%, 3 missing values) had 
evoked pain of at least moderate intensity.
Of the patients, 8/104 (8%) reported current use of NP 
medication: 5/8 used amitriptyline (10–50 mg per day), 1/8 
nortriptyline (75 mg per day), 2/8 pregabalin (300–375 mg 
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per day), and 2/8 venlafaxine (75 mg per day). Other pain 
medication was used by 25/104 (24%) patients: 15/25 used 
acetaminophen, 14/25 nonsteroidal anti-inflammatory drugs 
(NSAID), and 6/25 mild opioids. None of the patients used 
strong opioids.
Quantitative sensory testing
QST profiles on the breast and ICBN area are shown for 
the surgical (affected) and the unaffected side in Fig. 2. 
On the affected side, the z-scores indicated a significant 
(p < 0.001) loss of function in all items except for WUR, 
PPT and VDT compared with the reference data [27]. PPT 
and VDT showed a significant (p < 0.01) gain of function. 
On the unaffected side, the z-scores indicated a significant 
(p < 0.01) loss of function compared with the reference 
data for CDT, WDT, TSL, and MDT. MPS, VDT, and PPT 
showed a significant (p < 0.01) gain of function.
When comparing with the unaffected side, the z-scores 
on the affected side differed significantly (p < 0.05) in 
CDT, WDT, TSL, CPT, HPT, MDT, and MPT both on 
the breast and on the ICBN area (Fig. 2). MPS differed 
significantly on the breast and VDT on the ICBN area 
Fig. 1  Patient flow chart
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compared with the unaffected side. PHS was significantly 
more frequent in the affected side in both tested areas.
In patients who had the QST performed on the ICBN 
area, we tested how the handling of ICBN may affect the 
sensory function. The QST profiles for patients with spared, 
partially, and totally resected ICBN are shown in Fig. 3. 
Compared with spared ICBN, patients with total resection 
presented with more severe loss of function in the mechani-
cal tests for both small (MPT, MPS, WUR) and large (MDT, 
VDT) fiber function. However, the difference was signifi-
cant (p = 0.031) only for MDT. Patients with totally resected 
ICBN reported PHS more frequently, but the difference was 
not significant (p = 0.145).
Figure 4 presents sensory phenotypes according to the 
published algorithm [13, 14].”Sensory loss” was the most 
common phenotype (54/104, 52%) followed by “mechanical 
hyperalgesia” (38/104, 37%). “Thermal hyperalgesia” was 
present in 11/104 (11%) of patients. Sensory phenotype 
did not associate significantly to any of the factors listed in 
Table 1 or to the site of QST (data not shown). All patients 
with the “thermal hyperalgesia” phenotype had undergone 
BCR and all but one had received radiotherapy. Patients with 
different sensory phenotypes did not differ in terms of chem-
otherapy or endocrine therapy. Only one patient presented 
with a healthy phenotype.
The value for WUR was missing from 42/104 (40%) 
patients on the surgical side and from 11/104 (11%) on the 
unaffected side due to hyposensitivity to pinprick. Seven 
patients could not tolerate testing with the pressure algom-
eter device due to high sensitivity to pressure.
Bedside examination and sensory mapping
Sensory loss was the leading finding in BE: all patients 
except for two had sensory loss in at least one of the tested 
modalities (98%). Of these, 85/102 (83%) presented with 
sensory loss in all five modalities.
Sensory gain in BE was found in 38/104 (37%) patients. 
Of these, 11/38 (29%) had sensory gain in one modality, and 
4/38 (11%) in all five modalities. Sensory gain for pinprick 
was most prevalent (32/38, 84%).
The overlap and magnitude of the abnormal sensory 
areas are illustrated in Fig. 5. In a linear regression model, 
including the cancer- and treatment—related factors listed 
in Table 1, only ALND significantly associated with a larger 
area of sensory loss (beta 0.336, p = 0.028). Thus, we pre-
sented the overlap of the areas separately for patients with 
SLNB (n = 35) and ALND (n = 69). For clarity, all surgeries 
are illustrated on the left side. Of the surgeries, 50/104 (48%) 
were right-sided.
9/35 (26%) of the patients with SLNB and 63/69 (91%) 
of the patients with ALND had a surgeon-verified ICBN 
resection (p < 0.001).
We studied the association between sensory abnormalities 
and pain intensity (Table 2). The intensity of self-reported 
pain in the surgical area (0–10 NRS) correlated with the 
size of the area for sensory loss. For sensory gain, we used 
dichotomized variable (yes/no). Patients with sensory gain 
reported significantly higher intensities of pain (median 
NRS 3/10 vs. 1/10, p = 0.004) even after controlling for the 
axillary surgery type and age compared with those without 
sensory gain.
Comparison of the outcomes of BE and QST
BE and the corresponding QST items showed equal out-
comes in 34–57% of patients (Table 3). The QST z-scores 
did not differ significantly in patients with sensory gain, 
Table 1  Patient description
a One patient had received oxaliplatin for intestinal cancer
N = 104
Descriptives Mean (SD)
 Age (years) 62.3 (7.1)
 Time from surgery (months) 77.6 (14.0)
Characteristics of breast cancer N (%)
 Histology
  Intraductal carcinoma 67 (64.4)
  Intralobular carcinoma 19 (18.3)
  Other 18 (17.3)
 Gradus
  I 27 (26.0)
  II 42 (40.4)
  III 35 (33.7)
Cancer treatment N (%)
 Breast surgery type
  Breast conserving resection 83 (79.8)
   Mastectomy 21 (20.2)
Axillary surgery type
   Sentinel lymph node biopsy 35 (33.7)
     Axillary lymph node dissection 69 (66.3)
 Handling of ICBN
  Spared 22 (21.2)
  Partially resected 46 (44.2)
  Totally resected 26 (25.0)
  Not identified 10 (9.6)
 Chemotherapya 75 (72.1)
  Docetaxel 66 (63.4)
  Cyclophosphamide-ebirubicine-5-fluorouracil 72 (69.2)
 Radiotherapy 94 (90.4)
 Endocrine therapy 82 (78.8)
  Tamoxiphen 68 (65.4)
  Aromatase inhibitor 62 (59.6)
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sensory loss or normal finding in the corresponding BE 
test (data not shown).
The three QST phenotypes differed very little in BE. 
Only sensory loss to cold sensation in BE was signifi-
cantly (p = 0.007) less frequent in the “thermal hyperalge-
sia” group (4/11, 36%) compared with the “sensory loss” 
(44/54, 82%) and the “mechanical hyperalgesia” (29/38, 
76%) groups.
Discussion
In the DFNS QST of women with chronic post-surgical NP 
after breast cancer surgery, we found significant sensory 
loss in thermal and mechanical tests both in the affected 
and unaffected side when compared with the DFNS norma-
tive data. The affected side presented significant sensory 
Fig. 2  Comparison of the QST 
profiles on affected (surgi-
cal) and unaffected side. QST 
was performed on the area 
of breast in 43 (41%) and on 
the area of ICBN innervation 
(lateral breast, upper side of 
chest, axilla, upper medial 
arm) in 61 (59%). CDT cold 
detection threshold, CPT cold 
pain threshold, DMA dynamic 
mechanical allodynia, HPT heat 
pain threshold, ICBN intercosto-
brachial nerve, MDT mechani-
cal detection threshold, MPS 
mechanical pain sensitivity, 
MPT mechanical pain threshold, 
NRS numerical rating scale, 
PHS paradoxal heat sensation, 
PPT pressure pain threshold, 
QST quantitative sensory test-
ing, VDT vibration detection 
threshold, WDT warm detection 
threshold, WUR wind-up ratio
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loss in both thermal and mechanical tests compared with 
the unaffected side.
Patients with spared ICBN presented with similar sensory 
loss compared with resected ICBN. Of the sensory profiles, 
“sensory loss” was the most common (52%), followed by 
“mechanical hyperalgesia” (37%). Only 11% of patients, all 
having had BCR, presented with the “thermal hyperalgesia” 
profile.
In BE, sensory loss was the most prevalent (98%) finding. 
Sensory gain in BE was present in 37% and it was associated 
with more intense pain.
Quantitative sensory testing
Few previous studies have conducted QST (not with the 
DFNS protocol) on the painful surgical area in patients 
operated for breast cancer [15, 16, 29]. They report higher 
thermal and tactile detection thresholds in the operated side 
compared with the unaffected side, in line with our results. 
In the long-term, the post-surgical sensory dysfunction in 
breast cancer survivors seems to sustain with sensory loss.
Similar to our results, previous studies also report gain 
of function in PPT [15, 16, 30]. However, we observed sen-
sory gain in PPT both in the affected and unaffected side. 
The DFNS reference data on upper back may generate bias 
[27]. However, some patients were extremely sensitive even 
to light pressure. Moreover, widespread pressure-evoked 
hyperalgesia in non-surgical areas has been reported in 
patients operated for breast cancer [31]. Widespread sensory 
gain in PPT may reflect central sensitization in patients with 
NP after breast cancer treatments [31].
The effect of ICBN handling on chronic post-surgical 
pain is controversial [6]. Previously, it was reported that the 
risk of post-surgical pain increased if the surgeon spared 
ICBN [32]. However, in another recent study, resection of 
ICBN increased risk for NP [5].
We found a considerable sensory impairment in the ICBN 
area even when the nerve was spared from resection. This 
suggest that the patients who have NP in the ICBN innerva-
tion area have similarly impaired sensory function regardless 
of the surgical nerve handling. Therefore, other perioperative 
lesions (e.g., compression, stretching, and scar formation) to 
ICBN, not only mere resection, may play an important role 
in post-surgical NP. Our results highlight the importance of 
QST in further studies to better understand the effect of the 
type of nerve injury on post-surgical NP.
Interindividual differences in sensory profiles may reflect 
distinct pathophysiological backgrounds with different 
responses to medical treatments [13, 14, 28]. A recently pub-
lished algorithm stratifies patients to three different patho-
logical phenotypes according to the sensory profile in DFNS 
Fig. 3  QST profiles for patients 
with spared (n = 11), partially 
(n = 26), and totally (n = 20) 
resected ICBN. CDT cold 
detection threshold, CPT cold 
pain threshold, DMA dynamic 
mechanical allodynia, HPT heat 
pain threshold, ICBN intercosto-
brachial nerve, MDT mechani-
cal detection threshold, MPS 
mechanical pain sensitivity, 
MPT mechanical pain threshold, 
NRS numerical rating scale, 
PHS paradoxal heat sensation, 
PPT pressure pain threshold, 
QST quantitative sensory test-
ing, VDT vibration detection 
threshold, WDT warm detection 
threshold, WUR wind-up ratio
Fig. 4  Sensory phenotypes for breast conserving resection (BCR) and 
mastectomy
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QST [13]. There are a few studies that support the idea of 
personalized NP treatments according to sensory phenotype 
[10, 13, 33].
Frequencies of the three QST phenotypes vary across 
NP etiologies [8]. In our cohort of chronic post-surgical 
NP patients, “sensory loss” was the most prevalent (52%) 
reflecting the loss of both small and large nerve fiber func-
tion. Pain may be generated by ectopic activity at the sites 
proximal to injury [8, 34]. 37% in this cohort belonged to 
the “mechanical hyperalgesia” phenotype characterized by 
central sensitization to mechanical stimuli and sensory loss 









































Fig. 5  Areas of sensory abnormalities in BE on the side of surgery 
in patients with SLNB or ALND. Overlap of areas of sensory loss or 
gain in BE including light touch (cotton tuft), dynamic touch (paint-
er’s brush), static allodynia (compression of finger), pinprick (cock-
tail stick), cold and warm sensation (metal roller). Sensory loss refers 
to hypoestesia and sensory gain refers to hyperestesia, dysestesia, or 
allodynia in any of these sensory modalities. For clarity, all surger-
ies are shown on left side. ALND axillary lymph node dissection, BE 
bedside examination, ICBN intercostobrachial nerve, SLNB sentinel 
lymph node biopsy
Table 2  Associations between pain intensity and sensory sings in the surgical area
Arb. unit arbitrary unit, Beta standardized regression coefficient, IQR interquartile range, NRS Numerical Rating Scale, rS Spearman’s rho
p-values < 0.05 are shown in bold. Since the majority of the patients did not have positive sensory sings, the variable is dichotomized for the 
analysis. Arb. unit refers to the measure of the area in the body maps
a Adjusted for the following: age and type of axillary surgery
Self-reported pain (0–10 NRS) Bivariable analyses Multivariable  adjustmenta
Positive sensory signs median (IQR) p-value Beta p-value
Yes 3 (1–4) 0.004 0.243 0.014
No 1 (0–3)
rS p-value Beta p-value
Negative sensory sings (arb. 
units)
0.350  < 0.001 0.175 0.090
All sensory sings (arb. units) 0.365  < 0.001 0.183 0.081
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“Thermal hyperalgesia” was the most infrequent (11%) 
phenotype in our cohort. It is considered as a peripheral sen-
sitization phenotype with possible response to oxcarbazepine 
treatment [10, 13]. It may reflect effective nerve regeneration 
[13], which could be hindered by radiotherapy after breast 
cancer surgery [35]. The high prevalence of radiotherapy in 
our cohort (90%) may partly explain the scarcity of “thermal 
hyperalgesia” phenotype. However, all patients with “ther-
mal hyperalgesia” had undergone BCR. This is in line with 
a previous study reporting less severe sensory impairment 
in BCR compared with mastectomy [15].
The distribution of the sensory phenotypes in our cohort 
differs from the previously published data on patients with 
NP after peripheral nerve injuries reporting “thermal hyper-
algesia” as the most prevalent phenotype (40%) [13]. This 
may suggest that post-surgical NP after breast cancer treat-
ment is distinct from other nerve injury derived NP (possibly 
due to postoperative radiotherapy) and most patients may not 
benefit from  Na+ -channel blockers.
Clinical BE and sensory mapping
ALND has been associated with persistent post-surgical pain 
[32], which could be due to the increased risk for periopera-
tive ICBN lesions [15]. In our cohort, however, the presence 
of sensory gain in BE associated with more intense pain, but 
not with the type of surgery or treatment. Most patients with 
sensory gain in BE, reported hyperesthesia/hyperalgesia to 
pinprick, which may involve both central and peripheral sen-
sitization mechanisms [36].
Although sensory loss was the most common finding in 
both BE and QST, the individual outcomes of corresponding 
tests in BE and QST were consistent in only 29–57% of the 
patients. Similar results were observed in a previous study 
on 32 patients with traumatic partial nerve injury [37]. The 
differences in the applied stimuli and conduct of the meas-
urement may explain this inconsistency. Since QST exam-
ines a restricted area of interest with a standardized protocol, 
it may reveal impairment in the sensory function that does 
not emerge in BE [38].
The standardized protocol, training, equipment, and ref-
erence data of the DFNS QST aim to improve quality and 
comparability of the data from different centers. However, 
although BE is more robust and mainly qualitative it is a 
critical step of NP diagnostics and it allows the sensory map-
ping of the whole affected area. BE and QST are compli-
mentary, rather than substitutive methods of assessment of 
the sensory function. QST offers a means to stratify patients 
to certain sensory phenotypes that is not accessible by BE. 
This could be important to consider in the future if the sen-
sory phenotype-based treatment design gains further support 
[13].
Strengths and limitations
Strengths of the study are a relatively large and thoroughly 
characterized patient cohort of post-surgical NP patients. 
One examiner conducting BE to all patients excludes the 
need to consider inter-rater variability.
Most of the patients did not use regular NP medications 
or other analgesics. These medications may affect the sen-
sory profile, especially the evoked pain thresholds. However, 
the patients reported of scarce usage of these medications.
Lack of healthy controls is a limitation of the study, since 
the DFNS normative data were from the back [27]. However, 
we were able to compare the affected and the unaffected side 
with each patient as her own control. Some QST items show 
high levels of variation among healthy individuals [26]. 
Therefore, a reliable set of normative values may require a 
large number of healthy controls. Normative data collected 
Table 3  Frequency of 
equal outcomes in bedside 
examination and quantitative 
sensory testing
BE bedside examination, CDT cold detection threshold, CPT cold pain threshold, HPT heat pain threshold, 
MDT mechanical detection threshold, MPS mechanical pain sensitivity, MPT mechanical pain threshold, 
PPT pressure pain threshold, QST quantitative sensory testing, TSL thermal sensory limen
Clinical sensory test Axon type Corresponding QST 
item
Equal outcome 
in BE and QST
Static mechanical allodynia C PPT 33/94 (34%)
Light touch Aβ MDT 58/102 (57%)
Dynamic touch Aβ MDT 58/103 (56%)
Pinprick Aδ MPT 38/103 (37%)
MPS 52/99 (53%)
Cold sensation Aδ CDT 49/104 (47%)
CPT 30/102 (29%)
TSL 57/104 (55%)
Warm sensation C WDT 47/104 (45%)
HPT 36/102 (35%)
TSL 53/104 (51%)
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from multiple centers would benefit further studies of the 
sensory function in breast cancer patients.
Conclusions
We describe DFNS QST sensory profiling and sensory 
mapping of patients with post-surgical NP several years 
after breast cancer treatments. DFNS QST may improve 
NP patient phenotyping, which cannot be achieved by BE, 
and lead more precise NP treatment strategies. In addition, 
QST may provide information on perioperative nerve inju-
ries, which may help in post-surgical NP diagnostics. Our 
results suggest that post-surgical NP after breast cancer sur-
gery differs from other nerve injury derived NP. We need 
further studies combining QST to specific responses to NP 
medications.
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